GlassScriptPhysician profile
Chindo Bala Mallum
NPI 1669968160
$8,888.63
in general payments reported to CMS, 2019-2025
47 companies · $1,921 in 2025
The $1,921 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,322 · 2023: $2,702 · 2024: $2,943 · 2025: $1,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,771 · Education: $462 · Travel and Lodging: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,770.74 |
| Education | $461.94 |
| Travel and Lodging | $333.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $1,281.82 | 2022 | |
| Abbvie INC. | $778.00 | 2023-2025 | |
| Livanova USA, INC. | $729.45 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $635.03 | 2023-2025 | Briviact, Rystiggo, Fintepla |
| Emd Serono, INC. | $503.20 | 2023-2025 | Mavenclad, Mavenclad |
| Jazz Pharmaceuticals INC. | $424.65 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $411.49 | 2023-2025 | Ultomiris, Soliris |
| Eisai INC. | $387.83 | 2022-2025 | |
| Tg Therapeutics, INC. | $315.26 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $311.67 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $302.66 | 2023-2024 | Austedo Xr |
| Argenx US, INC. | $207.17 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurelis, INC. | $204.17 | 2023-2025 | Valtoco |
| Lundbeck LLC | $197.44 | 2023-2024 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $194.20 | 2023-2025 | Wakix |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $191.10 | 2023-2025 | Kisunla, Emgality, Amyvid |
| Axsome Therapeutics, INC. | $146.50 | 2025 | Symbravo |
| Sk Life Science, INC. | $141.64 | 2023-2024 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $126.80 | 2023-2024 | Rexulti, Nuedexta |
| Genzyme Corporation | $121.60 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.60 | 2025 | Zeposia |
| Mdd US Operations, LLC | $121.60 | 2025 | |
| Pfizer INC. | $117.77 | 2023-2024 | |
| Catalyst Pharmaceuticals, INC. | $97.20 | 2023 | Fycompa |
| Amgen INC. | $91.61 | 2024-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $76.42 | 2023-2025 | Nuplazid |
| Genentech USA, INC. | $68.73 | 2024 | Ocrevus, Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $64.39 | 2023-2024 | Ingrezza |
| Banner Life Sciences, LLC | $52.33 | 2023-2024 | |
| Celgene Corporation | $43.24 | 2025 | Zeposia |
| Biogen, INC. | $41.79 | 2022-2023 | Skyclarys |
| Tonix Medicines, INC. | $37.93 | 2024-2025 | Zembrace Symtouch |
| Cycle Pharmaceuticals INC | $33.92 | 2025 | Bafiertam |
| Sumitomo Pharma America, INC. | $30.44 | 2023 | Aptiom |
| Ipsen Biopharmaceuticals, INC | $29.59 | 2025 | Dysport |
| Averitas Pharma INC. | $27.61 | 2024 | Qutenza |
| Kyowa Kirin, INC. | $25.90 | 2024 | Nourianz |
| Grifols USA, LLC | $25.75 | 2024 | Gamunex-C |
| Csl Behring | $24.63 | 2023 | Hizentra |
| Merz Pharmaceuticals, LLC | $23.56 | 2025 | Inbrija, Xeomin |
| Azurity Pharmaceuticals, INC. | $23.56 | 2023 | Horizant |
| Boston Scientific Corporation | $22.82 | 2025 | Watchman Flx |
| Octapharma USA, INC. | $16.53 | 2024 | Panzyga |
| Medtronic, INC. | $16.08 | 2023 | Percept PC Brainsense |
| Acorda Therapeutics, INC | $15.57 | 2023 | Inbrija, Ampyra |
| Idorsia Pharmaceuticals US INC | $13.63 | 2023 | Quviviq |
| Amylyx Pharmaceuticals, INC. | $12.75 | 2023 | Relyvrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chindo Mallum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.